Active Ingredient(s):Sacituzumab Govitecan-hziy FDA Approved: * April 22, 2020 Pharm Company: *IMMUNOMEDICS INC Category:Cancer
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.
The most common side effects include nausea, neutropenia, diarrhea, fatigue, anemia, vomiting, alopecia (hair loss), constipation, decreased appetite, rash and abdominal pain.[8&am...
* May have multiple approval dates, manufacturers, or labelers.